Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)
China · Delayed Price · Currency is CNY 14.75
-0.03 (-0.20%)
Apr 14, 2026, 3:00 PM CST
SHA:600161 Revenue
In the year 2025, Beijing Tiantan Biological Products had annual revenue of 6.17B CNY with 2.26% growth. Beijing Tiantan Biological Products had revenue of 1.70B in the quarter ending December 31, 2025, a decrease of -13.05%.
Revenue
6.17B
Revenue Growth
+2.26%
P/S Ratio
4.73
Revenue / Employee
1.16M
Employees
5,298
Market Cap
29.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.17B | 136.17M | 2.26% |
| Dec 31, 2024 | 6.03B | 851.42M | 16.44% |
| Dec 31, 2023 | 5.18B | 919.14M | 21.57% |
| Dec 31, 2022 | 4.26B | 149.15M | 3.63% |
| Dec 31, 2021 | 4.11B | 666.56M | 19.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chongqing Zhifei Biological Products | 10.91B |
| Shanghai RAAS Blood Products | 7.35B |
| Asymchem Laboratories (Tianjin) | 6.67B |
| Shanghai Allist Pharmaceuticals | 5.17B |
| Yili Chuanning Biotechnology | 4.62B |
| Hualan Biological Engineering | 4.60B |
| Xiamen Amoytop Biotech | 3.70B |
| Sinocelltech Group | 1.56B |